Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.
about
HIV and aging: emerging research issuesThe role of statins in the setting of HIV infectionImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.The end of AIDS: HIV infection as a chronic diseaseAlterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors.Systemic effects of inflammation on health during chronic HIV infectionInitiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study.Persistent immune activation in chronic HIV infection: do any interventions work?Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort.Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on StatinsPreventing Heart Failure in Inflammatory and Immune DisordersAssociations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patientsThe Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients.Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental deathThe next therapeutic challenge in HIV: polypharmacy.Pathophysiology and management of cardiovascular disease in patients with HIVMetabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapyCardiovascular disease and HIV infection.Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection.Coronary artery disease in patients with HIV infection.Epidemiology of ischemic heart disease in HIV.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionTenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.HIV as a Cause of Immune Activation and Immunosenescence.Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.Epigenetic alterations are associated with monocyte immune dysfunctions in HIV-1 infection.Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis.
P2860
Q27016011-DFC381B3-81F5-4ECC-A88A-5EA075976677Q27027724-8696463D-567F-4C5C-841A-1635FB79DD22Q27687272-6F316455-26B5-4BF5-9654-1F9BA321468CQ28300749-DE1B78C3-838F-47B2-8EE0-5EC1CDF6CD7CQ33569492-EE24C8A5-ACAA-431B-9EF6-9E668CF28788Q33577551-5A8C4BA3-052F-4411-B402-725AC52C52FDQ33649200-88A41BFB-78C8-4ED9-9EEA-488A7D06BE0AQ34612901-160EAF19-CB2C-4985-9D78-0FE95D137E9EQ34851102-4EE4194C-FC42-4BEB-9A56-E11C3D3914CAQ35115728-04A4C97C-B03F-40E2-8690-89EA11CA842BQ35705439-59ADC0F2-DB9C-4A2F-94F1-4A4129A2F54CQ35894666-DF81340B-B142-48D9-855A-BB34CE8247A7Q35994802-1AC126F9-87A7-4905-B5F4-4C715D758BD3Q36243241-D0ED7CAF-B479-4E53-A748-ED16667CF8CBQ36516798-0676FC82-7D18-4924-8404-C1F8949BA38BQ36956948-5997AB81-386D-4B39-B104-A2BDC7D43DA2Q37025385-BA535A59-26BD-4444-9BEC-CCE5D7B13CDEQ37038775-C77BAF25-C443-4078-9FC1-615150FEE365Q37418053-7A138940-499D-4875-ACAC-57906C88F5B6Q37418140-268F554C-89ED-4721-BC61-C19E2897F006Q37528422-5E60BBD5-D512-4E11-9F5D-7AC22A4B2DEEQ37661603-15076AE6-5693-4976-99F0-5DDED0072806Q38066127-B82E1353-2E8E-4FB3-B824-2B9373AE42BAQ38172305-35B0DADE-FDF6-49EF-99F7-D0FB8D9667B3Q38352065-7D20A59C-7549-459B-949B-F99879FA59BBQ38629009-DE47BCA4-75A6-40CC-AE76-34131FD5F45FQ38749963-A951CB2B-D7B7-4334-9523-87BC37A3E820Q42228871-9314244F-7210-42F7-A188-107B63E67259Q47151081-727EE1AC-79C6-4123-AE1E-4DB65E8E39FBQ52645402-931CC5C2-8486-41CB-815B-9338FE1A372EQ54679094-C0704EE1-FEA9-4AE4-97F1-A00C4AA391CBQ55491369-BB9F8794-387C-4D0A-B18D-D599BF086270
P2860
Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Association between use of HMG ...... lity in HIV-infected patients.
@ast
Association between use of HMG ...... lity in HIV-infected patients.
@en
type
label
Association between use of HMG ...... lity in HIV-infected patients.
@ast
Association between use of HMG ...... lity in HIV-infected patients.
@en
prefLabel
Association between use of HMG ...... lity in HIV-infected patients.
@ast
Association between use of HMG ...... lity in HIV-infected patients.
@en
P2093
P2860
P1433
P1476
Association between use of HMG ...... lity in HIV-infected patients.
@en
P2093
Joel E Gallant
John G Bartlett
Richard D Moore
P2860
P304
P356
10.1371/JOURNAL.PONE.0021843
P407
P577
2011-07-12T00:00:00Z